Alison Lap-Tak Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alison Lap-Tak Ma has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
Wai-Ming Lai
Paediatric Nephrology Centre, Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital
8 shared publications- Eugene Yu-Hin Chan
Paediatric Nephrology Centre, Hong Kong Children’s Hospital, Kowloon, Hong Kong SAR
7 shared publications Pak-Chiu Tong
Paediatric Nephrology Centre, Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital
6 shared publicationsFanny Tsz-Wai Ho
Paediatric Nephrology Centre, Hong Kong Children’s Hospital, Hong Kong SAR, China
5 shared publicationsEugene Yu-Hin Chan
Paediatric Nephrology Centre, Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital
4 shared publicationsStella Chim
Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital
4 shared publications
Latest Publications
- Open Access
- 19 November 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (11)
Overweight and Rapid Weight Gain Following Pediatric Kidney Transplantation in Chinese Children
Aim: This study aimed to descriptively characterize posttransplant weight gain trajectories, obesity prevalence, and explore factors associated with weight gain in Chinese pediatric kidney transplant recipients, a population for whom such data remain limited. Methods: We conducted a retrospective cohort study of all Chinese children who received kidney transplants in Hong Kong from 2013 to 2023. Primary outcome was BMI Z scores, assessed at baseline and serially posttransplant using local reference data. Rapid weight gain was defined by ≥ 0.5 increase in BMI Z score or ≥ 10% increase in body weight during the first‐year posttransplant. Results: Fifty‐three Chinese children (59% male; median age at transplant 13.3 years, IQR, 7.9–17.8) were analyzed and followed for 6.1 years (IQR, 2.8–8.1). Mean BMI Z score increased significantly from baseline to 1‐year posttransplant (Δ = +0.47 SD, p = 0.0001). The prevalence of overweight/obesity significantly increased from 13.2% at baseline to 30.2% at 1 year ( p = 0.05). Rapid weight gain occurred in 64.2% of patients. In exploratory analyses, family history of obesity (46.7% vs. 13.5%; p = 0.03) and overweight/obesity prior to transplant (31.3% vs. 5.4%; p = 0.02) were associated with 1‐year overweight/obesity. Cardiometabolic outcomes and kidney function were comparable between patients with or without rapid weight gain. Conclusions: Significant weight gain is common following pediatric kidney transplant. Early screening, identification, and timely intervention are keys to halt disease progression.
- 19 November 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (11)
Open AccessOverweight and Rapid Weight Gain Following Pediatric Kidney Transplantation in Chinese Children
Aim: This study aimed to descriptively characterize posttransplant weight gain trajectories, obesity prevalence, and explore factors associated with weight gain in Chinese pediatric kidney transplant recipients, a population for whom such data remain limited. Methods: We conducted a retrospective cohort study of all Chinese children who received kidney transplants in Hong Kong from 2013 to 2023. Primary outcome was BMI Z scores, assessed at baseline and serially posttransplant using local reference data. Rapid weight gain was defined by ≥ 0.5 increase in BMI Z score or ≥ 10% increase in body weight during the first‐year posttransplant. Results: Fifty‐three Chinese children (59% male; median age at transplant 13.3 years, IQR, 7.9–17.8) were analyzed and followed for 6.1 years (IQR, 2.8–8.1). Mean BMI Z score increased significantly from baseline to 1‐year posttransplant (Δ = +0.47 SD, p = 0.0001). The prevalence of overweight/obesity significantly increased from 13.2% at baseline to 30.2% at 1 year ( p = 0.05). Rapid weight gain occurred in 64.2% of patients. In exploratory analyses, family history of obesity (46.7% vs. 13.5%; p = 0.03) and overweight/obesity prior to transplant (31.3% vs. 5.4%; p = 0.02) were associated with 1‐year overweight/obesity. Cardiometabolic outcomes and kidney function were comparable between patients with or without rapid weight gain. Conclusions: Significant weight gain is common following pediatric kidney transplant. Early screening, identification, and timely intervention are keys to halt disease progression.
- Open Access
- 26 August 2026
- Published by Elsevier in Kidney International
- Vol. 110 (5) , 1126-1140
Outcomes from the International Society of Nephrology forum on complement therapeutics in C3 glomerulopathy and IgA nephropathy
- 26 August 2026
- Published by Elsevier in Kidney International
- Vol. 110 (5) , 1126-1140
Open AccessOutcomes from the International Society of Nephrology forum on complement therapeutics in C3 glomerulopathy and IgA nephropathy
- 27 July 2026
- Published by Elsevier in Kidney International
- Vol. 110 (4) , 841-850
Secondary thrombotic microangiopathy in children—a central role for the glycocalyx
- 27 July 2026
- Published by Elsevier in Kidney International
- Vol. 110 (4) , 841-850
Secondary thrombotic microangiopathy in children—a central role for the glycocalyx
- 7 July 2026
- Published by Elsevier in Kidney International
- Vol. 110 (4) , 807-811
Complement inhibition in STEC-HUS: rationale versus evidence
- 7 July 2026
- Published by Elsevier in Kidney International
- Vol. 110 (4) , 807-811
Complement inhibition in STEC-HUS: rationale versus evidence
- Open Access
Long-Term Kidney Outcomes in Paediatric Osteosarcoma Survivors: A 20-Year Multi-Centre Study
Background: The long-term kidney outcomes in paediatric osteosarcoma survivors treated with nephrotoxic chemotherapeutic agents are not well-described. Methods: We conducted a multi-centre retrospective cohort study and recruited paediatric osteosarcoma survivors who survived beyond 5 years from cancer diagnosis over a 20-year period. Chronic kidney disease (CKD) was defined as evidence of kidney impairment, chronic tubulopathy, and proteinuria upon last follow-up. Results: We included 89 patients (57% males) with a mean follow-up period of 14.9 years. A total of 42 subjects (47.2%) developed CKD, 28 of whom had CKD stage 1 with either chronic tubulopathy or proteinuria; 14 patients had CKD stage 2 (eGFR < 90 mL/min/1.73 m2), while two had CKD stage 3 (eGFR < 60 mL/min/1.73 m2). Chronic tubular dysfunction was reported in 34 patients (38%), with hypomagnesemia being the most common manifestation. Proteinuria and hypertension were infrequently observed, in 3% and 8% of cases, respectively. We found that a history of severe AKI and aminoglycoside exposure during the treatment course were significant risk factors for CKD, but the dose-dependent relationships between the development of CKD and cisplatin, ifosfamide, and methotrexate could not be demonstrated. Conclusions: CKD is prevalent among paediatric osteosarcoma survivors. Caution is needed when using multiple nephrotoxic agents at the same time, as this could increase the risk of CKD in the long run. Multi-disciplinary regular surveillance should be performed to identify and manage CKD early, including kidney function, electrolyte, and proteinuria monitoring.
Open AccessLong-Term Kidney Outcomes in Paediatric Osteosarcoma Survivors: A 20-Year Multi-Centre Study
Background: The long-term kidney outcomes in paediatric osteosarcoma survivors treated with nephrotoxic chemotherapeutic agents are not well-described. Methods: We conducted a multi-centre retrospective cohort study and recruited paediatric osteosarcoma survivors who survived beyond 5 years from cancer diagnosis over a 20-year period. Chronic kidney disease (CKD) was defined as evidence of kidney impairment, chronic tubulopathy, and proteinuria upon last follow-up. Results: We included 89 patients (57% males) with a mean follow-up period of 14.9 years. A total of 42 subjects (47.2%) developed CKD, 28 of whom had CKD stage 1 with either chronic tubulopathy or proteinuria; 14 patients had CKD stage 2 (eGFR < 90 mL/min/1.73 m2), while two had CKD stage 3 (eGFR < 60 mL/min/1.73 m2). Chronic tubular dysfunction was reported in 34 patients (38%), with hypomagnesemia being the most common manifestation. Proteinuria and hypertension were infrequently observed, in 3% and 8% of cases, respectively. We found that a history of severe AKI and aminoglycoside exposure during the treatment course were significant risk factors for CKD, but the dose-dependent relationships between the development of CKD and cisplatin, ifosfamide, and methotrexate could not be demonstrated. Conclusions: CKD is prevalent among paediatric osteosarcoma survivors. Caution is needed when using multiple nephrotoxic agents at the same time, as this could increase the risk of CKD in the long run. Multi-disciplinary regular surveillance should be performed to identify and manage CKD early, including kidney function, electrolyte, and proteinuria monitoring.
- Open Access
- 23 February 2026
- Published by Springer Nature in Pediatric Nephrology
- p. 1-25
Infection prophylaxis following anti-CD20 monoclonal antibodies in childhood kidney diseases
Anti-CD20 monoclonal antibodies (mAbs), which act as B-cell–depleting therapies, are now regarded as important treatments for a range of paediatric kidney diseases. Despite their effectiveness in achieving B-cell depletion and consequent disease remission, concerns remain regarding their side effect profile. These include infusion reactions, hypogammaglobulinaemia, and neutropenia, as well as infections. At present, the evidence supporting preventive measures such as intravenous immunoglobulin (IVIG) replacement and antibiotic prophylaxis remains inconclusive. In this review, we summarise the existing data on infection-related risks following anti-CD20 therapy and propose practical strategies to mitigate infection risk tailored to this group of children. Graphical Abstract
- 23 February 2026
- Published by Springer Nature in Pediatric Nephrology
- p. 1-25
Open AccessInfection prophylaxis following anti-CD20 monoclonal antibodies in childhood kidney diseases
Anti-CD20 monoclonal antibodies (mAbs), which act as B-cell–depleting therapies, are now regarded as important treatments for a range of paediatric kidney diseases. Despite their effectiveness in achieving B-cell depletion and consequent disease remission, concerns remain regarding their side effect profile. These include infusion reactions, hypogammaglobulinaemia, and neutropenia, as well as infections. At present, the evidence supporting preventive measures such as intravenous immunoglobulin (IVIG) replacement and antibiotic prophylaxis remains inconclusive. In this review, we summarise the existing data on infection-related risks following anti-CD20 therapy and propose practical strategies to mitigate infection risk tailored to this group of children. Graphical Abstract
- 1 July 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (2) , 346-348
The Art of Healing
An abstract is unavailable. This article is available as a PDF only.
- 1 July 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (2) , 346-348
The Art of Healing
An abstract is unavailable. This article is available as a PDF only.
- 18 June 2025
- Published by Springer Nature in Pediatric Radiology
- Vol. 55 (8) , 1622-1631
Utility of the modified computed tomography severity index in prognostication of acute pancreatitis in children
Background The ability to predict severe pancreatitis in children remains a challenge, and limited evidence exists in the literature regarding the utility of different prognostication systems. Objectives To assess the utility of the modified computed tomography severity index (mCTSI) in predicting clinical outcomes in paediatric patients with acute pancreatitis. Materials/methods A single-centre, retrospective review of all patients diagnosed with acute pancreatitis who underwent contrast-enhanced computed tomography of the abdomen and pelvis from January 2019 to December 2024. The performance in predicting the development of organ dysfunction of mCTSI, computed tomography severity index (CTSI), and C-reactive protein (CRP) level at 48 h of admission was compared. Results We included 47 patients. Patients who developed organ dysfunction had a higher median mCTSI (8 [interquartile range, IQR 6–10]) compared to those who did not (4 [IQR 2–6], P < 0.001). In patients who had mCTSI ≥ 4, i.e. moderate and severe grades, the median length of PICU stay was significantly longer (mCTSI < 4 = 0 [IQR 0–0] days; mCTSI ≥ 4 = 3 [IQR 0–9] days, P < 0.001). Receiver operating characteristic analysis demonstrated mCTSI as a better predictor of organ dysfunction with an area under curve (AUC) of 0.891 (95% confidence interval [CI] 0.799–0.983), compared to CRP level which had an AUC of 0.596 (95% CI 0.433–0.759) (P = 0.002). No significant difference was identified between mCTSI and CTSI. Conclusions Both mCTSI and CTSI were useful in predicting the clinical outcome of patients with acute pancreatitis and performed better than CRP level in predicting the development of organ dysfunction. Graphical Abstract
- 18 June 2025
- Published by Springer Nature in Pediatric Radiology
- Vol. 55 (8) , 1622-1631
Utility of the modified computed tomography severity index in prognostication of acute pancreatitis in children
Background The ability to predict severe pancreatitis in children remains a challenge, and limited evidence exists in the literature regarding the utility of different prognostication systems. Objectives To assess the utility of the modified computed tomography severity index (mCTSI) in predicting clinical outcomes in paediatric patients with acute pancreatitis. Materials/methods A single-centre, retrospective review of all patients diagnosed with acute pancreatitis who underwent contrast-enhanced computed tomography of the abdomen and pelvis from January 2019 to December 2024. The performance in predicting the development of organ dysfunction of mCTSI, computed tomography severity index (CTSI), and C-reactive protein (CRP) level at 48 h of admission was compared. Results We included 47 patients. Patients who developed organ dysfunction had a higher median mCTSI (8 [interquartile range, IQR 6–10]) compared to those who did not (4 [IQR 2–6], P < 0.001). In patients who had mCTSI ≥ 4, i.e. moderate and severe grades, the median length of PICU stay was significantly longer (mCTSI < 4 = 0 [IQR 0–0] days; mCTSI ≥ 4 = 3 [IQR 0–9] days, P < 0.001). Receiver operating characteristic analysis demonstrated mCTSI as a better predictor of organ dysfunction with an area under curve (AUC) of 0.891 (95% confidence interval [CI] 0.799–0.983), compared to CRP level which had an AUC of 0.596 (95% CI 0.433–0.759) (P = 0.002). No significant difference was identified between mCTSI and CTSI. Conclusions Both mCTSI and CTSI were useful in predicting the clinical outcome of patients with acute pancreatitis and performed better than CRP level in predicting the development of organ dysfunction. Graphical Abstract
- 3 April 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 40 (7) , 2413
Voices of Resilience – integrating psychosocial support and music for children with kidney disease
- 3 April 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 40 (7) , 2413
Voices of Resilience – integrating psychosocial support and music for children with kidney disease
- Open Access
- 21 February 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (3) , sfaf052
Humoral and cellular immunogenicity of a fourth dose BNT162b2 in children with chronic kidney diseases
Background: Children with chronic kidney disease (CKD) are at risk of severe complications after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and are recommended to receive vaccine boosters. Although coronavirus disease 2019 (COVID-19) boosters are effective in providing immune responses among healthy children, data on the use of a fourth dose among children with CKD are limited. Methods: We prospectively investigated the immunogenicity and safety of a fourth dose of BNT162b2 in children with CKD. Dosages were 0.1 mL and 0.3 mL for children aged 5–11 years and 11–18 years, respectively. Humoral and cellular immunogenicity was assessed at pre-dose 4, and at 1 and 6 months post-dose 4. Results: Twenty-one children, with a median age of 14.0 years, were included for evaluation. A fourth dose of BNT162b2 elicited significant increases in humoral spike receptor–binding domain immunoglobulin G levels and T-cell responses. Antibody responses were significantly lower among kidney transplant recipients or children receiving calcineurin inhibitors than other CKD children at 1 month post-dose 4. Breakthrough COVID-19 occurred in three children after the fourth dose, and one was hospitalized. One child developed mild gross hematuria 1 day after the fourth dose, which spontaneously resolved. The overall safety profile was acceptable. Conclusions: A fourth dose of BNT162b2 was immunogenic and safe in children with CKD.
- 21 February 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (3) , sfaf052
Open AccessHumoral and cellular immunogenicity of a fourth dose BNT162b2 in children with chronic kidney diseases
Background: Children with chronic kidney disease (CKD) are at risk of severe complications after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and are recommended to receive vaccine boosters. Although coronavirus disease 2019 (COVID-19) boosters are effective in providing immune responses among healthy children, data on the use of a fourth dose among children with CKD are limited. Methods: We prospectively investigated the immunogenicity and safety of a fourth dose of BNT162b2 in children with CKD. Dosages were 0.1 mL and 0.3 mL for children aged 5–11 years and 11–18 years, respectively. Humoral and cellular immunogenicity was assessed at pre-dose 4, and at 1 and 6 months post-dose 4. Results: Twenty-one children, with a median age of 14.0 years, were included for evaluation. A fourth dose of BNT162b2 elicited significant increases in humoral spike receptor–binding domain immunoglobulin G levels and T-cell responses. Antibody responses were significantly lower among kidney transplant recipients or children receiving calcineurin inhibitors than other CKD children at 1 month post-dose 4. Breakthrough COVID-19 occurred in three children after the fourth dose, and one was hospitalized. One child developed mild gross hematuria 1 day after the fourth dose, which spontaneously resolved. The overall safety profile was acceptable. Conclusions: A fourth dose of BNT162b2 was immunogenic and safe in children with CKD.